KLOW: Side effects, risks and reviews
The safety profile of KLOW is unknown, as the mixture has never been evaluated. This page compiles what health authorities and research say about its components, without minimizing its limitations.
Key takeaways
- No safety studies have been published on the KLOW mixture.
- Human data are scarce for BPC-157, and absent according to the FDA for TB-500 and KPV.
- French authorities have received reports about several of these peptides.
- BPC-157 and TB-500 are banned by the World Anti-Doping Agency.
Official alerts
In France, the ANSM (National Agency for Medicines and Health Products Safety) issued an alert on July 2, 2026, regarding peptides sold online, with instructions not to use them. The Île-de-France pharmacovigilance center specified on July 23, 2026, that reports concerned, in particular, BPC-157, GHK-Cu, and TB-500. The described effects range from nausea to severe allergic reactions, and some individuals required hospitalization. The center reiterates that these products are not authorized, that their long-term effects are poorly understood, and urges the public to report any adverse effects.
In the United States, the FDA cites a risk of immunogenicity—that is, an immune system reaction—related to peptide aggregation or impurities for BPC-157, TB-500, and injectable GHK-Cu. It also notes a lack of safety data.
What we know, peptide by peptide
| Peptide | Data available | Point of caution |
|---|---|---|
| GHK-Cu | Well known in cosmetics, but little human data on injections | Risk of immunogenicity raised by the FDA for injectable forms |
| BPC-157 | Three small studies, 30 people, low methodological quality | Long-term safety unknown |
| TB-500 | No human exposure data identified by the FDA for this fragment | Aggregation and impurities reported |
| KPV | No human exposure data identified by the FDA | Unknown safety profile |
Details of GHK-Cu can be found on the page GHK-Cu injection or cream.
Why the blend adds uncertainty
Knowing each component is not enough to understand a mixture. Several questions remain unanswered: can the peptides interact with each other, does the copper in GHK-Cu alter the stability of the other peptides in solution, and how can an observed effect be attributed to one of the four? An analytical report answers a different question, that of the vial's contents. It provides no proof of safety, and our Janoshik report does not address sterility or endotoxins.
KLOW and anti-doping
Since 2022, the World Anti-Doping Agency has banned BPC-157 in and out of competition, placing it in class S0 of unapproved substances. TB-500 is classified in class S2 of peptide hormones and growth factors. A vial of KLOW contains both of these substances and therefore falls under these prohibitions.
How reliable are the reviews of KLOW?
Numerous testimonials can be found on Reddit and social media, mentioning symptoms such as fatigue or local reactions. These testimonials do not allow for any definitive conclusions: they are unverified, the actual composition of the products is unknown, and the effects could stem from something other than the peptide. Both positive and negative testimonials should be read with equal caution. The advertised benefits are detailed on a separate page: what the studies say.
- KLOW: The Complete Guide
- Benefits: what studies say
- KLOW, GLOW or Wolverine
- Our Janoshik (COA) analysis
- The mechanisms of KLOW (article)
Frequently asked questions
What are the side effects of KLOW?
These effects are not established, as the mixture has never been studied. For peptides sold online, French reports range from nausea to severe allergic reactions.
Is KLOW dangerous?
Its safety has not been assessed. The ANSM (French National Agency for Medicines and Health Products Safety) issued a warning in July 2026 about peptides sold online, and BPC-157, GHK-Cu and TB-500 are cited among the reports.
Is KLOW banned in sports?
Yes: it contains BPC-157 (class S0) and TB-500 (class S2), both of which are banned by the World Anti-Doping Agency.
Does a certificate of analysis guarantee the safety of KLOW?
No. It indicates what the vial contains. It says nothing about tolerance, and ours does not address sterility or endotoxins.
What to do in case of an adverse effect?
Consult a healthcare professional and report the effect to your regional pharmacovigilance center, on signalement-sante.gouv.fr.
Sources: ANSM, alert of 02/07/2026; Île-de-France Pharmacovigilance Center, 23/07/2026; FDA, substances for compounded preparations (April 2026); systematic review, Acta Orthop Belg (PubMed 42885452); USADA. MyPeptide products are intended exclusively for scientific research in the laboratory.
